Nextcure, INC 10-Q quarterly reports

NextCure, Inc. reported its Q2 2026 results, detailing a significant net loss and substantial doubt about its going concern status, while simultaneously announcing a proposed merger with Avere Therapeutics and a comprehensive restructuring plan.

NextCure reports a net loss of $9.8 million for Q1 2026, with cash reserves dwindling, while advancing its lead drug candidates SIM0505 and LNCB74.

NextCure, Inc. reported a net loss of $8.6 million for Q3 2025 and disclosed substantial doubt about its ability to continue as a going concern, necessitating immediate capital raises.

NextCure, Inc. reported a significant increase in net loss for Q2 2025, driven by a new licensing agreement, while also disclosing substantial doubt about its ability to continue as a going concern.

NextCure, Inc. announces its Q1 2025 financial results, reporting a net loss of $10.976 million and highlighting the advancement of its LNCB74 clinical trial.

NextCure Inc. announced its third quarter 2024 results, highlighting a strategic pipeline prioritization and a cash runway extended into the second half of 2026.

NextCure, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results, highlighting a focus on key clinical programs and a restructuring plan to extend its cash runway.

NextCure, Inc. announced its first quarter 2024 financial results, highlighted by a strategic restructuring to focus on key clinical programs and extend its cash runway into the second half of 2026.